"The fundamentals have always been strong, but we are seeing increased understanding that biotech companies are in fact commercializing medical research, and that is contingent upon the entire ecosystem functioning well. We have seen an expressed intention from government to grow innovation, and the sector clearly has the potential to lead Australia's transition to an innovation-based economy."
Glenn Cross, AusBiotech CEO, commenting on a survey of Australian biotech CEOs compiled by consulting firm Grant Thornton Read More
Collaboration has become increasingly important in drug development. There's a consortium for seemingly every disease as well as those designed to increase clinical trial efficiency and large-scale screening of compounds.
Read More
Insights into the role of the microbiome in human disease represented one of the hottest tickets in town at Digestive Disease Week (DDW) 2017 in Chicago. Multiple biopharmas have efforts afoot to marshal the beneficial microorganisms that colonize the human body even though researchers are still endeavoring to show cause and effect between microbiota – the microorganisms that live in an established environment – and disease. One major question still confronting the field, for instance, is whether dysbiosis causes or results from intestinal inflammation, since the evidence doesn't yet point to an irrefutable conclusion.
Read More
